GHRP Class Comparison: GHRP-2, GHRP-6, Ipamorelin, and Hexarelin in Research

Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.

Introduction

The growth hormone-releasing peptides (GHRPs) are a family of small synthetic peptides — typically penta- or hexapeptides — that bind the growth hormone secretagogue receptor type 1a (GHSR-1a), the same receptor activated by the endogenous peptide ghrelin. Following the foundational work of Cyril Bowers in the 1980s, this class has expanded to include four primary research-grade members: GHRP-2, GHRP-6, Ipamorelin, and Hexarelin. A systematic GHRP class comparison reveals important differences in receptor selectivity, secondary hormone effects (notably ACTH and cortisol release), and downstream applications in preclinical research.

All four compounds share a common primary target — GHSR-1a on pituitary somatotrophs and hypothalamic neurons — and a common downstream effect: stimulation of pulsatile growth hormone release. Where they differ is in selectivity: the extent to which they activate secondary endocrine pathways including hypothalamic-pituitary-adrenal (HPA) axis activation, prolactin release, and appetite stimulation through orexigenic pathways. These differences shape how each peptide is used in research and define their distinct experimental applications.

The GHSR-1a Receptor System

The growth hormone secretagogue receptor type 1a (GHSR-1a) is a Class A G protein-coupled receptor identified in the mid-1990s and subsequently demonstrated to be the endogenous receptor for ghrelin — a 28-amino-acid stomach-derived peptide characterized in 1999. Activation of GHSR-1a couples primarily to Gαq, leading to phospholipase C activation, IP₃ generation, and intracellular calcium elevation. In pituitary somatotrophs, this signaling cascade triggers growth hormone secretion. In hypothalamic neurons of the arcuate nucleus, GHSR-1a activation modulates NPY/AgRP-expressing neurons and influences appetite signaling. GHSR-1a is also expressed in the heart, pancreas, and adrenal cortex — distribution that underlies some of the off-target effects observed with non-selective ligands.

A defining feature of GHSR-1a biology is its constitutive activity: in the absence of any ligand, the receptor exhibits substantial basal signaling, with roughly 50% of maximal activity reported in some heterologous expression systems. This constitutive activity has functional consequences for receptor pharmacology — inverse agonists (compounds that reduce signaling below basal) and neutral antagonists (compounds that block ligand binding without affecting basal signaling) have distinct preclinical research applications. For the four GHRPs covered in this article, all act as agonists of GHSR-1a, increasing signaling above basal.

The endogenous ligand ghrelin is unique among peptide hormones in requiring acylation at Ser³ with an n-octanoic acid moiety for full GHSR-1a binding affinity. This acylation is catalyzed by ghrelin O-acyltransferase (GOAT), and the relative abundance of acylated versus des-acylated ghrelin in circulation has emerged as a regulated component of the ghrelin system. Synthetic GHRPs, by contrast, do not require lipid modification for activity and engage GHSR-1a through their constrained peptide structures alone. This distinction is one of the reasons GHRPs serve as useful pharmacological probes complementary to native ghrelin in research designs.

Compound-by-Compound Comparison

1. GHRP-2 (Pralmorelin)

GHRP-2 is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂) developed by Bowers and colleagues. It is a potent ghrelin receptor agonist with documented secondary effects on the HPA axis. Laferrère et al. (2005) demonstrated that GHRP-2 administration in healthy humans significantly increased food intake, consistent with its ghrelin-mimetic activity on appetite circuits [1]. Massoud et al. (1996) characterized the effects of GHRP-2 and Hexarelin on GH, prolactin, ACTH, and cortisol levels in humans, finding that both peptides produce measurable ACTH and cortisol elevation — though less than CRH itself [2]. Bowers et al. (1990) provided the foundational characterization of GHRP-2 as a potent GH-releasing peptide following intravenous and subcutaneous administration [9]. In research applications, GHRP-2 is used in studies of GH pulsatility, appetite signaling, and HPA axis activation. Research-grade GHRP-2 is supplied for preclinical investigations across these domains.

2. GHRP-6

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) and was one of the earliest GHRPs characterized by Bowers. Of all members of the GHRP class, GHRP-6 produces the most pronounced appetite stimulation, making it the preferred research tool for studying ghrelin-mediated orexigenic pathways. Like GHRP-2, GHRP-6 elevates ACTH and cortisol secretion at higher doses. Tolle et al. (2001) demonstrated that the central responsiveness to GHRP-6 is rapidly altered by acute nutritional status changes in rats — consistent with its role as a ghrelin mimetic linked to feeding behavior [3]. Korbonits et al. (2006) compared the effects of ghrelin, GHRP-6, and GHRH in Cushing’s disease patients, characterizing the divergent ACTH-releasing potency of these compounds [4]. Cibrián et al. (2006) reported that GHRP-6 attenuated cytokine-induced damage in cultured cardiomyocytes, providing an early indication of cardioprotective activity within the GHRP class beyond classical GH-releasing biology [10]. GHRP-6 is most often used in research models of appetite regulation, gastric motility, and ghrelin signaling.

3. Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk in the late 1990s and characterized by Raun et al. (1998) as “the first selective growth hormone secretagogue” [5]. Its distinguishing feature is high selectivity for GH release with minimal activation of secondary endocrine pathways — particularly low elevation of ACTH, cortisol, prolactin, and aldosterone compared with other GHRP-class peptides. This selectivity profile makes Ipamorelin particularly valuable in research designs aimed at isolating GH-specific effects from broader HPA axis confounders. Ipamorelin has been evaluated in preclinical and clinical research for postoperative ileus, gastric motility, and broader endocrine investigations. Beck et al. (2014) reported Phase II clinical data on ipamorelin for postoperative ileus in bowel resection patients [6]. Aagaard et al. (2002) characterized Ipamorelin pharmacokinetics in beagle dogs and showed concentration-dependent GH release with a relatively short plasma half-life [11]. Research-grade Ipamorelin is widely used in preclinical GH pulsatility research, often in combination with GHRH analogs to study dual-receptor synergy.

4. Hexarelin

Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) derived from GHRP-6 by methylation of the second tryptophan residue, conferring greater enzymatic stability and potency. Beyond GH-releasing activity at GHSR-1a, Hexarelin exhibits a distinctive feature: high-affinity binding to CD36, a cardiac scavenger receptor. Bodart et al. (1999) identified and characterized this novel growth hormone-releasing peptide receptor in the heart [7]. Subsequent research has explored the cardiovascular actions of Hexarelin, with studies suggesting cardioprotective effects in models of ischemia-reperfusion injury and pressure overload [8]. Hexarelin also produces measurable ACTH and cortisol elevation, comparable to GHRP-2. Its dual GHSR-1a/CD36 binding profile makes it a unique research tool — and notably distinct from the other GHRPs — for studies of cardiac peptide signaling. McDonald et al. (2020) reviewed the broader cardiovascular biology of growth hormone secretagogues, summarizing preclinical evidence for direct and indirect cardiac effects of Hexarelin and related peptides [12].

Selectivity Comparison Table

Research Design Implications

The selectivity profile of each GHRP guides its use in preclinical research. Ipamorelin is the preferred research tool when the experimental question requires isolated GHSR-1a activation without HPA-axis confounders — for example, studies of GH-dependent metabolic effects, IGF-1 signaling, or muscle protein synthesis. GHRP-2 and GHRP-6 are useful when researchers wish to study integrated ghrelin-receptor biology, including appetite signaling, gastric motility, or HPA axis interactions. Hexarelin occupies a unique niche owing to its CD36 binding, making it particularly relevant to cardiovascular research models examining cardioprotection, fibroblast biology, and contractility studies.

Researchers should also consider combination strategies with GHRH analogs. GHRPs (acting at GHSR-1a) and GHRH analogs (acting at GHRHR) engage distinct receptor systems through complementary downstream signaling pathways. Co-administration of an Ipamorelin/CJC-1295 combination — for example — produces additive or synergistic GH release in preclinical and clinical research compared with either compound alone, with the GHRP component contributing pulse amplitude enhancement and the GHRH component contributing temporal patterning.

Decision Framework for GHRP Selection

The following sequential framework helps efficiently match a GHRP to a research design:

1. What is the primary endpoint? If the design measures GH-only effects (IGF-1 elevation, muscle protein synthesis, GH-dependent gene expression), Ipamorelin’s selectivity profile is the strongest choice. If the design measures integrated ghrelin biology (appetite, gastric motility, cortisol-GH interactions), GHRP-2 or GHRP-6 is appropriate. If the design focuses on cardiovascular endpoints (cardiomyocyte signaling, ischemia-reperfusion, CD36-dependent effects), Hexarelin is the unique tool.
2. Is HPA axis activation a desired or undesired effect? All GHRPs except Ipamorelin produce measurable ACTH and cortisol elevation. For studies in which adrenal axis activation is a confounder, Ipamorelin is preferred. For studies in which integrated GH-cortisol-stress biology is the topic of investigation, GHRP-2 or GHRP-6 may be more informative.
3. Will the GHRP be paired with a GHRH analog? If yes, match the half-life of the GHRP to the half-life of the GHRH analog. Short-acting GHRP + short-acting GHRH (e.g., Ipamorelin + Mod GRF 1-29) produces a brief well-defined GH pulse. Short-acting GHRP + long-acting GHRH (e.g., Ipamorelin + CJC-1295 with DAC) creates sustained GHRH receptor engagement with episodic GHSR-1a engagement.
4. What is the planned route of administration? All four GHRPs are bioactive subcutaneously and intravenously in preclinical research. Some GHRPs (GHRP-2, in particular) have been studied via intranasal and oral routes; bioavailability via these routes is lower but documented.
5. What is the species and model context? GHSR-1a is well-conserved across mammals, but rodent and human responses can differ in dose-response slope and HPA axis sensitivity. Researchers should consult species-specific pharmacokinetic data when extrapolating.

Common Research Pitfalls

Several recurring pitfalls appear in GHRP preclinical research that should be addressed in study design:

• Treating all GHRPs as interchangeable. Despite the shared GHSR-1a target, the four GHRPs differ substantially in HPA axis activation, appetite stimulation, secondary receptor binding (Hexarelin/CD36), and dose-response slope. Equimolar substitution of one GHRP for another in a study design will not produce equivalent biological effects.
• GHSR-1a desensitization with chronic dosing. Sustained or repeated GHRP administration produces receptor desensitization that attenuates the GH response over time. Long-duration GHRP studies should incorporate intermittent dosing schedules or build receptor desensitization into the analytic framework.
• Ignoring secondary endocrine endpoints. Studies focused on GH may overlook coincident elevations in ACTH, cortisol, and prolactin (for GHRP-2, GHRP-6, Hexarelin), which can be biologically significant confounders. Comprehensive endocrine panels — not GH alone — provide a more complete picture.
• Failure to account for ghrelin-mediated appetite effects in metabolic studies. GHRP-6 in particular drives substantial appetite increases; metabolic studies pairing GHRP-6 with energy balance endpoints must control for food intake or use pair-feeding designs.
• Inappropriate cross-species dose extrapolation. GHRP effective doses in mice, rats, dogs, and humans differ by factors that are not simply explained by body weight scaling. Allometric scaling alone is insufficient; species-specific dose-response characterization is appropriate.
• Neglecting CD36 effects when using Hexarelin. Hexarelin’s CD36 binding can produce cardiovascular effects independent of GH release. Studies using Hexarelin as a “GHRP” without acknowledging CD36 contribute to data interpretation difficulties in the cardiac literature.

Research Considerations for Laboratory Use

All four GHRPs are typically supplied as lyophilized powders at ≥98% HPLC purity. Storage at −20°C is standard for long-term archiving; reconstituted solutions should be maintained at 2–8°C and used within 2–4 weeks. Bacteriostatic water is the standard reconstitution solvent. Each lot should be accompanied by a Certificate of Analysis documenting sequence identity, purity, and counterion content. For research designs requiring dose accuracy across multiple peptide injections, analytical confirmation of reconstituted concentration is recommended before initiating extended studies.

The four GHRPs have molecular weights ranging from approximately 711 Da (Ipamorelin, the smallest) to 887 Da (GHRP-2). Equimolar dosing across the class is recommended for comparative research designs. Concentration calculations should account for the counterion mass — most synthetic peptides are supplied as TFA salts, contributing measurable mass to the lyophilized material. For sensitive cellular assays where TFA may be a confound, acetate salt forms can be requested and should be documented on the CoA.

GHRP-2 and Ipamorelin in particular have well-characterized pharmacokinetic parameters in multiple species, with published plasma half-life data spanning rats, dogs, and humans. GHRP-2’s plasma half-life is approximately 30–60 minutes in humans following intravenous administration; Ipamorelin’s half-life is approximately 2 hours, contributing to its utility in research designs requiring a single sustained pulse rather than rapid resolution. Hexarelin shows the longest plasma half-life of the four (~70 minutes) owing to its enzymatic stability conferred by the 2-methylated tryptophan. These differences should inform sampling protocols.

For combination studies with GHRH analogs, the most-studied pairings are Ipamorelin + Mod GRF 1-29 (matched short half-lives, both pulsatility-preserving) and Ipamorelin + CJC-1295 with DAC (Ipamorelin pulses superimposed on sustained CJC-1295 receptor activation). The biological response in each combination has been characterized in multiple preclinical studies, providing dose-response data that informs new study design. Researchers should be aware that combination GH responses can saturate at relatively low individual peptide doses, and dose-finding studies should explore the lower range of each peptide rather than assuming linear extrapolation from monotherapy ED50.

Conclusion

The four research-grade GHRP-class peptides — GHRP-2, GHRP-6, Ipamorelin, and Hexarelin — share a common primary mechanism (GHSR-1a agonism) but differ substantially in selectivity. Ipamorelin offers the cleanest GH-selective profile, GHRP-6 the strongest appetite-modulating activity, GHRP-2 a balanced profile across the GHRP-class endpoints, and Hexarelin a distinctive cardiac-tissue interaction through CD36. The choice among them depends on the research question — whether the experimental design requires isolated GHSR-1a activation, integrated ghrelin biology, or cardiac peptide signaling.

All four occupy active preclinical research roles, and the GHRP class as a whole remains a productive area of investigation in growth hormone biology, ghrelin signaling, and combination peptide research designs.

References

1. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611–614. PMID: 15699539.

1. Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab. 1996;81(12):4338–4341. PMID: 9285939.

1. Tolle V, Zizzari P, Tomasetto C, Rio MC, Epelbaum J, Bluet-Pajot MT. In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology. 2001;73(1):54–61. Central responsiveness to ghrelin mimetics. PMID: 15929744.

1. Leal-Cerro A, Torres E, Soto A, et al. Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing’s disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH. Pituitary. 2006;9(3):247–253. PMID: 16832586.

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822.

1. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. PMID: 25331030.

1. Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res. 1999;85(9):796–802. PMID: 10532947.

1. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253–258. PMID: 25278975.

1. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. PMID: 2108187.

1. Cibrián D, Ajamieh H, Berlanga J, et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond). 2006;110(5):563-573. PMID: 16451123.

1. Aagaard NK, Grøfte T, Greisen J, et al. Growth hormone secretagogue ipamorelin reduces glucocorticoid-induced loss of muscle protein synthesis in normal rats. Growth Horm IGF Res. 2002;12(5):342-348. PMID: 12213187.

1. McDonald H, Peart J, Kurniawan ND, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018;6(15):e13782. PMID: 30084236.

Explore our lab-tested GHRP-2 and Ipamorelin → /product/ghrp-2/ | /product/ipamorelin/